Pleco Therapeutics has signed an agreement whereby Pleco licenses intellectual property developed at The University of Texas MD Anderson Cancer Center with the aim of developing innovative treatments for leukemia patients. MD Anderson is based in Houston, Texas and ranks as one of the world’s most respected centres focused on cancer patient care, research, education and prevention.